# Impact of Variants on Elasomeran Mechanism

## How do updated formulations (variants of concern) affect the mechanism of Elasomeran?

Updated mRNA-1273 formulations shift the neutralizing antibody response toward enhanced variant-specific recognition while maintaining the core B cell memory and T cell activation mechanisms of the original vaccine platform, with bivalent versions balancing variant-targeted depth against cross-reactive breadth.

## Abstract

Updated mRNA-1273 formulations targeting SARS-CoV-2 variants of concern alter the immune response mechanism through differential neutralizing antibody profiles while maintaining the platform’s core immunological pathways. Monovalent variant-specific vaccines (mRNA-1273.351 targeting B.1.351, mRNA-1273.529 targeting BA.1) demonstrated superior neutralizing antibody responses against their target variants, with geometric mean ratios of 1.67-1.77 for BA.1 formulations and twofold improvements for B.1.351 formulations...

Cellular immune mechanisms, including CD4+ and CD8+ T cell responses measured in preclinical models, showed similar activation patterns to the original vaccine, with effector T cell expansion but not effector-memory phenotypes and waning within 6 months.

## Methods

We analyzed 10 sources from an initial pool of 200, using 8 screening criteria...

## Results

### Characteristics of Included Studies

The systematic review identified 10 sources examining updated mRNA-1273 (Elasomeran) formulations targeting SARS-CoV-2 variants of concern.

| Study                       | Full text retrieved? | Updated formulation(s)                               | Study type          | Population               | Primary focus                                         |
|-----------------------------|----------------------|----------------------------------------------------|---------------------|--------------------------|------------------------------------------------------|
| Ivan T Lee et al., 2023     | No                   | BA.1-monovalent (mRNA-1273.529), BA.1-bivalent (mRNA-1273.214) | Phase 3 RCT       | Adults ≥16 years, UK     | 3-month safety and immunogenicity of BA.1-containing boosters |
| Kai Wu et al., 2021         | No                   | mRNA-1273.351, mRNA-1273.211                       | Preclinical (mice) | Mice                     | Variant vaccine neutralization as primary or booster series |
| A. Choi et al., 2021        | Yes                  | mRNA-1273.351, mRNA-1273.211                       | Phase 2a clinical trial | Healthy adults (mean ages 47.5-63.8 years), US | Safety and immunogenicity of variant-modified boosters |

...

## Immunological Mechanisms Assessed

Studies evaluated multiple immunological mechanisms to characterize how updated formulations affect the immune response to SARS-CoV-2 variants.

### Mechanism type

| Mechanism type                | Measurement methods                                            | Studies assessing                       |
|--------------------------------|---------------------------------------------------------------|---------------------------------------|
| Neutralizing antibodies         | Pseudovirus neutralization assays (lentivirus-based, VSV-based); live virus focus-reduction neutralization test (FRNT) | All clinical and preclinical studies   |
| Binding antibodies              | ELISA measuring IgG against recombinant spike proteins        | Preclinical studies                     |
| CD8+ T cell responses          | H-2b-restricted immunodominant peptides, IFN-γ production    | Preclinical studies                     |
| CD4+ T cell responses          | H-2b-restricted immunodominant peptides, IFN-γ production; S-specific CD4 T cells | Preclinical studies and review         |
| B cell memory                  | Anamnestic response to boosting                               | Clinical booster studies                |
| Durability                     | Persistence at Day 29 and Month 3; up to 6 months post-vaccination | Clinical studies                        |

...

## Protection Against Breakthrough Infections

Data on breakthrough infection rates with updated formulations compared to original vaccines were limited, with most studies focusing on immunogenicity rather than clinical outcomes.

| Aspect                        | Findings                                                  |
|-------------------------------|----------------------------------------------------------|
| Study population               | B.1.617.2 breakthrough                                   |
| Disease severity               | Viral pneumonia with inflammation in breakthrough cases    |
| Variant-specific protection    | Updated formulations offered better protection vs homologous strains |

## Synthesis

The findings reveal systematic patterns in how updated mRNA-1273 formulations alter immunological mechanisms, with heterogeneity explained by specific variant targets, formulation strategy (monovalent vs bivalent), and the evolutionary timing of SARS-CoV-2 variants tested.

### Variant-Specific vs Broad Protection Trade-offs

Monovalent variant-specific vaccines (mRNA-1273.351, mRNA-1273.529) consistently showed superior neutralization against their target variants—but demonstrated reduced neutralization against ancestral strains.

### Dose-Dependent Breakthrough Risk

...

### Temporal Evolution and Escape Dynamics

The longitudinal analysis revealed progressive viral escape from both original and updated vaccine-induced immunity. Despite mechanistic improvements, newer variants continue to evade updated mRNA vaccines, highlighting the need for continual adaptation to vaccine development in response to viral evolution.